Skip to main content
Equibles
CODX logo

CODX · Co-Diagnostics, Inc. · Metrics

Track CODX — free

Use CODX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CODX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.26 -0.01 (-4.12%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued. These uncertainties create substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 10, 2026
Market Cap
$2.72M
Shares
10.51M
Volume · Nov 13 591.94K Avg daily vol (3M) 1.97M

CODX metrics

73 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.26
Market cap
$2.72M

Price action

23 metrics
Price change (1W)
+0.7%
Price change (30D)
-63.8%
Price change (3M)
-81.5%
Price change (6M)
-79.9%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$11.61
52-week low
$0.26
Change from 52-week high
-97.8%
Change from 52-week low
+0.7%
Annualized volatility
232.4%
Annualized volatility (3M)
123.3%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.3
RSI (14D)
23.3
Price vs SMA 50
-67.6%
Price vs SMA 200
-87.5%
Avg volume (3M)
1.97M
Relative volume
0.3
Average dollar volume
$781,279

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
10.51M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.3×
reciprocal yield 42.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.6%
P / book
0.3
reciprocal yield 346.7%
FCF yield
-1,000.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,746.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-10

Profitability

9 metrics
Gross margin
20.3%
Operating margin
-5,614.3%
Trailing 12 months
Net margin
-5,527.6%
Gross profit (TTM)
$174,077
Operating profit (TTM)
−$48.22M
Net income (TTM)
−$47.48M
Trailing 12 months
Diluted EPS (TTM)
$-23.07
FCF margin
-3,165.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$9.85

Growth

11 metrics
Revenue growth YoY
+94.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$858,888
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+396.6%
Year over year · more shares
Revenue CAGR (3Y)
-73.7%
Revenue CAGR (5Y)
-61.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-503.7%
Return on assets
-371.1%
Debt / equity
0.0
Current ratio
0.8
EBITDA (TTM)
−$47.27M
Free cash flow (TTM)
−$27.19M
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$714,803
Latest balance sheet
Cash & equivalents
$714,803
Total assets
$12.79M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$26.88M
Capital expenditures (TTM)
$307,268
R&D (TTM)
$18.76M
SG&A (TTM)
—
Stock compensation (TTM)
$980,025
R&D / revenue
2,184.2%
Stock compensation / revenue
114.1%

Ownership (13F)

9 metrics
13F filers
25
13F filer change QoQ
+11
Institutional ownership
5.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
11.6%
Private-fund adviser ownership
7.8%
Active holders' share change QoQ
+866.0%
Holder tenure
2.0
Price vs estimated holder cost
+0.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 2.2 days to cover
Days to cover
2.2d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1692415 CUSIP 189763204 13F (30d) 30 filings 20 filers Visit website Investor relations